MS
MYGN icon

Maven Securities’s Myriad Genetics MYGN Stock Holding History

Maven Securities’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,000
Closed -$1.22M – 1010
2024
Q2 		$1.22M Buy
+50,000
New +$1.1M 0.03% 486
2020
Q4 		– Sell
-50,000
Closed -$652K – 759
2020
Q3 		$652K Buy
+50,000
New +$633K 0.05% 335

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Maven Securities's MYGN Position: Q3 2024 in Review

Maven Securities sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 50,000 shares — an estimated $1.22M sold.

Maven Securities first reported a position in MYGN in Q3 2020 and held it in 2 quarters. The position peaked at $1.22M in Q2 2024. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

  • Maven Securities reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
  • Maven Securities sold 50,000 Myriad Genetics shares in Q3 2024, an estimated $1.22M.
  • Maven Securities first reported a position in Myriad Genetics in Q3 2020 and held it in 2 quarters.
  • Maven Securities's Myriad Genetics position peaked at $1.22M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Maven Securities's 13F filing for Q3 2024, filed 14 Nov 2024.